One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor.

A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

A polymer compound is provided which is changed from a water-insoluble state to a water-soluble state by irradiation with light. The polymer compound is represented by Formula (5), where A and B are a single bond or a functional group, R.sup.3, R.sup.4, and R.sup.9 are hydrogen or an alkyl group, and R.sup.6 and R.sup.7 are hydrogen, an alkyl group, or the like.

A polymer compound is provided which is changed from a water-insoluble state to a water-soluble state by irradiation with light. The polymer compound is represented by Formula (5), where A and B are a single bond or a functional group, R.sup.3, R.sup.4, and R.sup.9 are hydrogen or an alkyl group, and R.sup.6 and R.sup.7 are hydrogen, an alkyl group, or the like.

A polymer compound is provided which is changed from a water-insoluble state to a water-soluble state by irradiation with light. The polymer compound is represented by Formula (5), where A and B are a single bond or a functional group, R.sup.3, R.sup.4, and R.sup.9 are hydrogen or an alkyl group, and R.sup.6 and R.sup.7 are hydrogen, an alkyl group, or the like.

In an embodiment, the present disclosure pertains to a method of changing the glass transition temperature of a polymer. In some embodiments, the polymer includes at least one hydrazone-containing compound. In general, the methods of the present disclosure include one or more of the following steps of: (1) applying light to the polymer; and (2) thereby changing the glass transition temperature of the polymer. In another embodiment, the present disclosure pertains to a polymer having a light-adjustable glass transition temperature. In some embodiments, the polymer includes at least one hydrazone-containing compound.

In an embodiment, the present disclosure pertains to a method of changing the glass transition temperature of a polymer. In some embodiments, the polymer includes at least one hydrazone-containing compound. In general, the methods of the present disclosure include one or more of the following steps of: (1) applying light to the polymer; and (2) thereby changing the glass transition temperature of the polymer. In another embodiment, the present disclosure pertains to a polymer having a light-adjustable glass transition temperature. In some embodiments, the polymer includes at least one hydrazone-containing compound.

Provided is a graft copolymer and a treatment method which give excellent antifouling property to a substrate, especially a carpet. The graft copolymer has a trunk polymer having a hydroxyl group; and a branch having a C.sub.7-40 hydrocarbon group bonded to the trunk polymer at a carbon atom substituted with the hydroxyl group, wherein the branch has a repeating unit formed from an acrylic monomer represented by the formula: CH.sub.2═C(—X)—C(═O)—Y.sup.1—Z(—Y.sup.2—R).sub.n. The treatment method include applying the graft copolymer to the substrate.